Endowing plants with tolerance to virus infection by their preliminary treatment with short interfering RNAs
- 23 Downloads
RNA interference (RNAi) is one of the key defense mechanisms directed against virus infections in plants and other organisms. In this case in plants infected with viruses, short interfering RNAs (siRNAs) are formed from two-chain replicated forms of virus molecules of RNA. These siRNAs program one of the RNAi basic components, RNA-induced complex of genes silencing (RISC, RNA induced silencing complex) associated with sequence-specific removing virus RNA. Virus protein P19 is a suppressor of RNAi and is capable of trapping the siRNAs being formed before their binding with RISC. Here, it was shown that preliminary entering leaves of plants Nicotiana benthamiana Domin (before virus infecting) of siRNAs eluted from the complex P19/siRNA from the infected plant lowers development of infection symptoms induced by tomato bushy stunt virus (TBSV) in inoculated plants. Exogenous addition of suppressor-associated siRNAs to plants leads to not only lowering virus accumulation but also to survival of infected plants. Thus, it has been established that preliminary addition of virus siRNAs elevates plant tolerance to the virus infection by means of early programming RISC and activation of the defense action of RNAi.
KeywordsNicotiana benthamiana RNA interference siRNA gel chromatography complex P19/siRNA
virus suppressor protein
RNA-induced complex of genes silencing
short interfering RNAs
tomato bushy stunt virus
Unable to display preview. Download preview PDF.
- 2.Tabernero, J., Shapiro, G.I., LoRusso, P.M., Cervantes, A., Schwartz, G.K., Weiss, G.J., Paz-Ares, L., Cho, D.C., Infante, J.R., Alsina, M., Gounder, M.M., Falzone, R., Harrop, J., White, A., Toudjarska, I., et al., First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement, Cancer Discov., 2013, vol. 3, pp. 406–417.CrossRefPubMedGoogle Scholar
- 3.Schultheis, B., Strumberg, D., Santel, A., Vank, C., Gebhardt, F., Keil, O., Lange, C., Giese, K., Kaufmann, J., Khan, M., and Drevs, J., First-inhuman phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors, J. Clin. Oncol., 2014, vol. 32, pp. 4141–4148.CrossRefPubMedGoogle Scholar
- 5.DeVincenzo, J., Lambkin-Williams, R., Wilkinson, T., Cehelsky, J., Nochur, S., Walsh, E., Meyers, R., Gollob, J., and Vaishnaw, A., A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus, Proc. Natl. Acad. Sci. USA, 2010, vol. 107, pp. 8800–8805.PubMedGoogle Scholar
- 6.Chandra, P.K., Kundu, A.K., Hazari, S., Chandra, S., Bao, L., Ooms, T., Morris, G.F., Wu, T., Mandal, T.K., and Dash, S., Inhibition of hepatitis C virus replication by intracellular delivery of multiple siRNAs by nanosomes, Mol. Ther., 2012, vol. 20, pp. 1724–1736.CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Sendi, H., Mehrab-Mohseni, M., Foureau, D.M., Ghosh, S., Walling, T.L., Steuerwald, N., Zamor, P.J., Kaplan, K.J., Jacobs, C., Ahrens, W.A., Russo, M.W., Clemens, M.G., Shrum, L.W., and Bonkovsky, H.L., MiR-122 decreases HCV entry into hepatocytes through binding to the 3' UTR of OCLN mRNA, Liver Int., 2015, vol. 35, pp. 1315–1323.CrossRefPubMedGoogle Scholar
- 8.Burgyan, J., Virus induced RNA silencing and suppression: defense and counter defense, J. Plant Pathol., 2006, vol. 88, pp. 233–244.Google Scholar
- 11.Omarov, R.T., Ciomperlik, J.J., and Scholthof, H.B., RNAi-associated ssRNA-specific ribonucleases in Tombusvirus P19 mutant-infected plants and evidence for a discrete siRNA-containing effector complex, Proc. Natl. Acad. Sci. USA, 2007, vol. 104, pp. 1714–1719.CrossRefPubMedPubMedCentralGoogle Scholar